FR2342979A1 - (9,10)-Dihydro-ergosine prepn. - by catalytic hydrogenation of ergosine in dimethylformamide using 10 percent palladium on carbon - Google Patents

(9,10)-Dihydro-ergosine prepn. - by catalytic hydrogenation of ergosine in dimethylformamide using 10 percent palladium on carbon

Info

Publication number
FR2342979A1
FR2342979A1 FR7706209A FR7706209A FR2342979A1 FR 2342979 A1 FR2342979 A1 FR 2342979A1 FR 7706209 A FR7706209 A FR 7706209A FR 7706209 A FR7706209 A FR 7706209A FR 2342979 A1 FR2342979 A1 FR 2342979A1
Authority
FR
France
Prior art keywords
ergosine
dimethylformamide
effect
prepn
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7706209A
Other languages
French (fr)
Other versions
FR2342979B1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals and Chemical Co dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals and Chemical Co dd filed Critical Lek Pharmaceuticals and Chemical Co dd
Publication of FR2342979A1 publication Critical patent/FR2342979A1/en
Application granted granted Critical
Publication of FR2342979B1 publication Critical patent/FR2342979B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/02—Ergot alkaloids of the cyclic peptide type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

(I) and its acid addn. salts are prepd. by hydrogenation of ergosine in dimethylformamide with shaking, at normal press., in the dark using a 10% Pd/C catalyst and opt. converting (I) to its salts. (I) is used to treat arterial hypertension, peripheral angiopathy, cerebral circulatory troubles, cardiac arrythmia and migraine. It is administered parenterally or enterally in daily doses of 0.3-10 7g/70 kg Acute toxicity (methanesulphonate i.p. in mice LD50=72.2 mg/kg, i.p. in rats=N400mg/kg) and pharmacological tests (arterial press., effect on heart, antiadrenaline effect, antiserotonin effect) are described. The reaction is effected rapidly reducing by-prods. due to degradation and giving high yields of (I).
FR7706209A 1976-03-04 1977-03-03 (9,10)-Dihydro-ergosine prepn. - by catalytic hydrogenation of ergosine in dimethylformamide using 10 percent palladium on carbon Granted FR2342979A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
YU545/76A YU40275B (en) 1976-03-04 1976-03-04 Process for preparing 9,10-dihydro-ergosine and physiologically tolerated acid addition salts thereof

Publications (2)

Publication Number Publication Date
FR2342979A1 true FR2342979A1 (en) 1977-09-30
FR2342979B1 FR2342979B1 (en) 1980-10-03

Family

ID=25550399

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7706209A Granted FR2342979A1 (en) 1976-03-04 1977-03-03 (9,10)-Dihydro-ergosine prepn. - by catalytic hydrogenation of ergosine in dimethylformamide using 10 percent palladium on carbon

Country Status (11)

Country Link
JP (1) JPS52156900A (en)
AT (1) AT352301B (en)
BE (1) BE851961A (en)
CS (1) CS200506B2 (en)
DD (1) DD128612A5 (en)
DE (1) DE2708042A1 (en)
FR (1) FR2342979A1 (en)
HU (1) HU173239B (en)
NL (1) NL7702332A (en)
SE (1) SE7702254L (en)
YU (1) YU40275B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187522A1 (en) * 2015-05-20 2016-11-24 Noramco, Inc. Process for the preparation of oxymorphone freebase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1216213A (en) * 1954-12-03 1960-04-22 Cilag Spa Process for the preparation of dihydrogenated compounds of synthetic or natural derivatives of lysergic acid
FR2285885A1 (en) * 1974-09-27 1976-04-23 Sandoz Sa NEW PEPTIDIC AMIDES OF 6-ALKYL-ERGOLINE-8-CARBOXYLIC ACIDS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1011112A (en) * 1961-05-10 1965-11-24 Sandoz Ag Improvements in or relating to ergot alkaloids

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1216213A (en) * 1954-12-03 1960-04-22 Cilag Spa Process for the preparation of dihydrogenated compounds of synthetic or natural derivatives of lysergic acid
FR2285885A1 (en) * 1974-09-27 1976-04-23 Sandoz Sa NEW PEPTIDIC AMIDES OF 6-ALKYL-ERGOLINE-8-CARBOXYLIC ACIDS, THEIR PREPARATION AND THEIR APPLICATION AS MEDICINAL PRODUCTS

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187522A1 (en) * 2015-05-20 2016-11-24 Noramco, Inc. Process for the preparation of oxymorphone freebase

Also Published As

Publication number Publication date
JPS52156900A (en) 1977-12-27
FR2342979B1 (en) 1980-10-03
ATA134577A (en) 1979-02-15
NL7702332A (en) 1977-09-06
HU173239B (en) 1979-03-28
YU54576A (en) 1983-01-21
DE2708042A1 (en) 1977-09-08
DD128612A5 (en) 1977-11-30
AT352301B (en) 1979-09-10
BE851961A (en) 1977-07-01
CS200506B2 (en) 1980-09-15
YU40275B (en) 1985-12-31
SE7702254L (en) 1977-09-05

Similar Documents

Publication Publication Date Title
Akselrod et al. Hemodynamic regulation in SHR: investigation by spectral analysis
US4774244A (en) Use of pterin derivatives
Davies et al. Physiological responses to one-and two-leg exercise breathing air and 45 percent oxygen.
Fisler Cardiac effects of starvation and semistarvation diets: safety and mechanisms of action
EP0345038A3 (en) Non-beta-oxidizable fatty acid analogues with the effect to reduce the concentration of cholesterol and triglycerides in blood of mammals
ZA859805B (en) 6-thioxanthine derivatives
FR2342979A1 (en) (9,10)-Dihydro-ergosine prepn. - by catalytic hydrogenation of ergosine in dimethylformamide using 10 percent palladium on carbon
Georgopoulos et al. Effect of exercise on electrocardiograms of patients with low serum potassium
Magnus et al. Studies on the antitumor agent CC-1065: Regiospecific introduction of the oxygen functionality for the synthesis of the B/C component of CC-1065.
GB577862A (en) Improvements in and relating to platinum catalysts
FR2143073A1 (en) 1-(3,4-methylenedioxyphenyl)-2-alkylamino-ethanols - - with beta-blocking activity
GB1416286A (en) Production of propionic acid
Sayre et al. EXPLORING CARDIO-MUSCULAR COORDINATION DURING EXERCISE
PT67095A (en) 6-Piperazino morphanthridine hydrogen maleate - prepd. from 6-chloro-morphanthridine with piperazine in xylene, and having sedative and hypnotic activity
FR2405253A1 (en) 6-Piperazino morphanthridine hydrogen maleate - prepd. from 6-chloro-morphanthridine with piperazine in xylene, and having sedative and hypnotic activity
Loew Wolff-Parkinson-White syndrome
Hoshida et al. Excessive thromboxane A2 production during evoluting process in acute myocardial infarction
Tallarida et al. Quinidine Sulfate
ASANO Changes of ventricular movement of clam heart by nicotine
JPS53116357A (en) Preparation of 2,2'-methylene-bis-4,6-dialkylphenol
Lonsdale A Metabolic Disorder Similar to Acute Cardiac Beriberi
GB973850A (en) Preparation of cyclo-octadi-1,3-ene
IE46016L (en) D-homosteroid
ECKBERG et al. Acquired Right Bundle-Branch Block and Left Anterior Hemiblock in Ostium Primum Atrial Septal Defect: The authors reply
Watanabe Studies on the Standard Ink for Inkomater value

Legal Events

Date Code Title Description
ST Notification of lapse